RxDoctor Payments Data

Bernard Kim, MD

Pulmonary Disease · Los Angeles, CANPI 1184723231

Payments from drug & device makers

$9,467in general payments, 2019–2025

Across 421 payments — averaging $22.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$2K
  • GSK$1K
  • Insmed, Inc.$465
  • Regeneron Healthcare Solutions, Inc.$414
  • Pfizer$325
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$9,38799%
  • Education$811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,467 in reported general payments places this provider in the 75th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Medicare billing

Part B allowed, 2024
$109,588
Medicare patients
438
Services billed
1,060

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate31$378,970
Trelegy ElliptaFluticasone/Umeclidin/Vilanter328$221,817
Breztri AerosphereBudesonide/Glycopyr/Formoterol44$29,948
Breo ElliptaFluticasone/Vilanterol54$22,375
Albuterol Sulfate HfaAlbuterol Sulfate672$18,880
Advair HfaFluticasone Propion/Salmeterol45$15,737
EliquisApixaban31$12,830
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$10,691
Spiriva RespimatTiotropium Bromide20$10,126
Fluticasone Propionate HfaFluticasone Propionate36$8,399
Atrovent HfaIpratropium Bromide11$5,752
Qvar RedihalerBeclomethasone Dipropionate17$4,502
Incruse ElliptaUmeclidinium Bromide14$4,501
Wixela InhubFluticasone Propion/Salmeterol35$4,375
DuleraMometasone/Formoterol13$4,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$1,677$399,78770 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$1,416$251,234409 claims
AstraZenecaBreztri Aerosphere$2,201$29,94844 claims
PfizerEliquis$325$12,83031 claims
MerckDulera$226$4,35813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,261 pulmonary disease providers in California.

Other pulmonary disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →